{
    "id": 13376,
    "fullName": "ABL1 H396P",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 H396P lies within the protein kinase domain of the Abl1 protein (UniProt.org). H396P is predicted to lead to activation of Abl1 in structural analyses, and is associated Abl1 inhibitor resistance (PMID: 16424036, PMID: 21481795), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed Sep 2019).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3830,
                    "pubMedId": 16424036,
                    "title": "Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16424036"
                },
                {
                    "id": 1865,
                    "pubMedId": 21481795,
                    "title": "Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21481795"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "H396P",
    "createDate": "10/29/2015",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 119180,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130874969A>C",
        "cDna": "c.1187A>C",
        "protein": "p.H396P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12904,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 H396P were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 22972,
                "profileName": "BCR - ABL1 ABL1 H396P"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6341,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 H396P in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22972,
                "profileName": "BCR - ABL1 ABL1 H396P"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7977,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 V379I (90%), V379I/H396P (3%), and V379I/H396P (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26122,
                "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13562,
            "profileName": "ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22972,
            "profileName": "BCR - ABL1 ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23169,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26122,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119180,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130874969A>C",
            "cDna": "c.1187A>C",
            "protein": "p.H396P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}